Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028?
RegulaciónOne-OffTecnologíaSalud y medicinaAcciones1aManifold MarketsSin KYCDatos de resolución verificadosBien calibradoPronóstico comunitario actualSí 76.1%
Pronosticadores
5
Tipo de pregunta
binary
Metodología
Play-money forecasting platform
Tipo de fuente
Pronóstico
Datos de mercado
Actualizado hace 53 minutos
Retrasado6 ago 26, 4:06 UTC31 dic 27, 23:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
Will a human anti-aging drug trial with mortality or lifespan as primary endpoint be registered before 2030?
Manifold MarketsWill Gustavo Petro face a criminal trial before January 1, 2027?
Manifold MarketsWill any U.S. state formally announce plans to phase out human drivers by 2040?
Manifold MarketsWill Billy Evans' company succeed
Manifold MarketsOpenAI’s valuation end of November 2026?
PolymarketWill Anthropic stock begin public trading on or before November 6, 2026?
Manifold MarketsReglas
Will BGE-102 significantly reduce hsCRP in BioAge's Phase 2 QUELL-CV trial?
- BGE-102 is a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor discovered by BioAge Labs, Inc. (Nasdaq: BIOA).
- NLRP3 drives age-related chronic inflammation implicated in cardiovascular disease, metabolic disorders, and neurodegenerative conditions; BioAge has said its discovery platform nominated NLRP3 from analysis of human aging cohorts in which lower NLRP3 activity tracked with greater longevity (Aug 15, 2025).
- The company has also stated that its compounds engage a binding site and mechanism distinct from other NLRP3 inhibitors in development, with a composition-of-matter patent covering that site issued in January 2026 (Jan 12, 2026).
- Cardiovascular risk reduction is the lead indication.
- This market concerns the QUELL-CV primary endpoint only.
